Category Archive for "Research"

Home »

Digital Advertising: The 7 Habits of Highly Effective Ad Platforms

Considering marketing spending beyond the roughly $537B in global measured media, suggests a more than $1.5T market, where digital makes up less than 10%. Given the inherent advantages of digital – targeting, acquiring customers, tracking behavior, facilitating transactions, building loyalty,

Read More

ABBV/PCYC: Imbruvica’s US Pricing Has Room to Grow

Imbruvica’s only dosage form is a 140mg capsule, with a US price of $101.88. Most indications for which Imbruvica is currently approved are dosed with 3 capsules daily (420mg), for an annual treatment cost of $111,559 The average price for

Read More

AAPL: High Priced, Cause it Feels So Nice

The fashion focused Apple Watch will launch 4/24 with high prices and predictable functionality, yielding limited volumes, but reasonable revenues and excellent profits during the first year. The $349-$399 entry point is too high for most users, most of whom

Read More

Industrial Gas Pricing – Talking a Good Game

Our recent thoughts on Industrial Gas companies have focused on their ability to pull pricing and cost levers to grow top and bottom lines. We have been particularly focused on APD and what it will need to deliver to justify

Read More

WBA, CVS, RAD: There Are Simply Too Many Pharmacies & Now it Starts to Matter

Retail prescription margin growth has outpaced CPI since 1990, drug pricing since at least 2001, and any other major US retail setting’s gross margin growth since at least 2004 It’s not because we lack enough pharmacies, it’s because traditional drug

Read More

TMT Model Portfolio Update: Escaping the Death Watch

We assessed the valuations of 187 US traded large cap TMT stocks, separating their EV into near-term and long-term components and graphing them on these axes. In the framework, the names fall into quadrants that have interesting implications for trading.

Read More

SSR Health New Product Approval Portfolios & Supporting Data Update

Drug, biotech, and research-based spec pharma stocks tend to outperform their peers in the year or so before and after regulatory actions (‘PDUFA’ dates) on major new products, with a large portion of total risks being concentrated in the days

Read More

Net Neutrality: Reining in the Dumb Pipe Oligopoly

  The Title II reclassification of broadband reflects a sea change in policy and is a substantial threat to the long term growth and profitability assumptions at the core of cable and telco valuations. The overwhelming public support for restraints

Read More

Motive & Opportunity: The Convoluted Tale of Generic Price Inflation

Since early 2013, prices for generics sold in the US at retail have risen more than 40% on a sales weighted basis Three-quarters of this inflation was driven by straightforward median reversion: a host of products with very low prices

Read More

Quick Thoughts: TWTR – BOOM! There’s MAUs in Them Thar Tweets

–     TWTR doesn’t have a user problem – it has a registration problem, and it’s taking steps to fix it. Meanwhile, it has the most easily monetized platform this side of GOOG search. –     Adjusted for change in the integration

Read More
test